An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma

Backgroundβ-glucan has been reported to be a potential natural immune modulator for tumor growth inhibition. We aimed to evaluate the efficacy and safety of β-glucan plus immunotherapy and chemotherapy in the first-line treatment of advanced gastric adenocarcinoma.MethodsThis is a phase IB, prospect...

詳細記述

書誌詳細

出版年:	Frontiers in Immunology
主要な著者:	Yunqian Chu, Xuan He, Ya Xue, Hua Jiang, Chan Zhu, Chunjian Qi, Xing Zhang, Dongsheng Chen, Hanjue Dai, Qingying Xian, Wenyu Zhu
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2024-08-01
主題:	β-glucan camrelizumab chemotherapy first-line gastric cancer
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1448485/full